Shares fell more than 8% in premarket trading. The company said it was halting the development program in light of disappointing preclinical studies. Shares fell more than 8% in premarket trading. The ...
LEXINGTON, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results